Jefferies Adjusts Price Target on Moderna to $215
Jefferies has lowered its price target for Moderna, Inc. from $230 to $215.
Stocks · News reference
Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Jefferies has lowered its price target for Moderna, Inc. from $230 to $215.
Supermicro has launched and begun shipping its new Petascale all-flash storage server line, designed to support high-performance AI training and inference workloads.
The non-small cell lung cancer market is shifting toward precision, biomarker-guided treatment sequencing. ESMO 2026 presented Phase III data showing savolitinib plus osimertinib improved survival in MET-altered EGFR-mutated NSCLC, divarasib outperformed approved KRAS G12C inhibitors, and TROP2-directed ADCs demonstrated durable gains. The 7MM NSCLC market is projected to double from USD 33 billion in 2025 to USD 67 billion by 2036, driven by expanded screening, biomarker-driven therapies, and label expansions into earlier-stage disease.
H.C. Wainwright has initiated research coverage on Rezolve AI plc, assigning the stock a 'Buy' rating and a price target of $6.
Nayax Ltd. has introduced a new self-service Prepaid Card Kiosk designed to allow operators to sell and reload prepaid cards while accepting both card and cash payments.
The article compares two semiconductor infrastructure companies: Applied Materials, which manufactures chipmaking equipment, and Marvell Technology, which designs data center networking chips. While Marvell shows faster revenue growth (30.6% vs 21.4%), Applied Materials is recommended as the safer choice due to lower valuation multiples and reduced risk from Marvell's pending $115 billion acquisition of Lumentum Holdings.